NEW YORK--(BUSINESS WIRE)--Ophthotech Corporation today announced the initiation of patient enrollment in a pivotal Phase 3 clinical trial of its lead compound FovistaTM, an anti-platelet-derived growth factor (PDGF), which is being studied in combination with anti-VEGF therapy for the treatment of newly diagnosed patients with neovascular age-related macular degeneration (wet AMD). The announcement marks the treatment of the first patient in the global Fovista Phase 3 clinical program, which consists of three clinical trials evaluating the safety and efficacy of the Fovista/anti-VEGF combination. The three trials are expected to enroll a total of approximately 1,866 patients at up to approximately 225 centers internationally.
Help employers find you! Check out all the jobs and post your resume.
